Regarding the relationship between medical treatment and subtypes, chemotherapy wasused in 94.0% of patients with luminal B (HER2+) PR+ cancer and 68.8% of patients with luminalB (HER2+) PR– cancer (P=0.003) (Table2). Here, ERBB2 is linked to cancer.